Analysis the alpha-protein level in hepatitis patient as an aid in accessing the degree in which it generates to hcc

Thesis Abstract

Abstract
Hepatocellular carcinoma (HCC) is a primary liver cancer that often develops in patients with chronic hepatitis. Alpha-fetoprotein (AFP) is a well-known biomarker that is frequently used in the diagnosis and monitoring of HCC. However, the role of AFP in predicting the development of HCC in patients with hepatitis remains a topic of debate. This study aimed to analyze the alpha-fetoprotein (AFP) levels in hepatitis patients and assess its utility as an aid in predicting the progression to hepatocellular carcinoma (HCC). A systematic review and meta-analysis were conducted to evaluate the existing literature on this topic. The results of the meta-analysis revealed that elevated AFP levels in hepatitis patients were significantly associated with an increased risk of developing HCC. The pooled data showed a strong positive correlation between AFP levels and the progression to HCC, indicating that AFP can serve as a valuable biomarker in identifying patients at higher risk for developing liver cancer. Furthermore, subgroup analyses were performed to investigate the impact of different factors on the relationship between AFP levels and HCC development. The analyses indicated that factors such as age, gender, hepatitis B or C infection, and liver cirrhosis may influence the predictive value of AFP in assessing the risk of HCC. Overall, this study highlights the importance of monitoring AFP levels in hepatitis patients as a potential indicator of HCC development. Early detection of HCC is crucial for improving patient outcomes, and AFP can play a significant role in identifying high-risk individuals who may benefit from closer surveillance and timely intervention. In conclusion, the findings of this study support the use of alpha-fetoprotein as a valuable tool in assessing the degree to which hepatitis patients may progress to hepatocellular carcinoma. Further research is warranted to validate these results and explore additional biomarkers or diagnostic tools that can enhance the early detection and management of HCC in high-risk populations.